title: The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
abstract: BACKGROUND
  There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD).
  
  
  METHODS
  This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin-angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25-50 mg/day) were investigated for 12 months.
  
  
  RESULTS
  Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline.
  
  
  CONCLUSIONS
  The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors.
authors: Division of Kidney and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi- Shinbashi, Minato-Ku, Tokoyo, Japan. nobuotsuboi@aol.com
authors: Nobuo
authors: N
authors: Tsuboi
authors: Tetsuya
authors: T
authors: Kawamura
authors: Hideo
authors: H
authors: Okonogi
authors: Takeo
authors: T
authors: Ishii
authors: Tatsuo
authors: T
authors: Hosoya
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D000077545:Eplerenone; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D015999:Multivariate Analysis; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone